Pulling SEC filings + quote and writing the call…

UPEXI, INC.
Next earnings Sep 18, 2026 · consensus $-0.12 EPS, $7.72M rev
Last earnings +3.0% on 2026-05-13
A shrinking consumer-brands shell repurposed into a levered, dilution-funded Solana bet — a speculation, not an investable business.
Revenue $15.8M · FY2025
Upexi is no longer really a consumer-products company; per the MD&A it is 'in the cryptocurrency industry and the management of cash assets through a cryptocurrency portfolio, primarily focused in Solana.' The legacy branded-products business is in outright decline: FY2025 revenue fell 39% to $15.8M (management cites a 43% drop, driven ~85% by divesting the recommerce business), and the five-year trajectory is ugly — $24.1M (2021) → $23.1M → $36.4M → $26.0M → $15.8M, with net losses every year since 2021 totaling well over $50M (accumulated deficit -$60.5M). Operating margin is -79% and operating cash flow was -$8.4M. Only ~$985K of revenue came from the new digital-asset treasury. This is a business shrinking into a crypto holding vehicle.
The balance sheet looks superficially strong — total assets jumped 427% to $124M and equity 1,283% to $90.1M — but that expansion came entirely from issuing stock: shares outstanding exploded 5,557% (to 58.9M) to fund Solana purchases. So the $90M of equity is largely a pile of SOL tokens, an asset whose value is volatile and unknowable from this filing. Meanwhile actual cash is just $2.98M against $20.0M of current debt, and the Risk Factors explicitly warn of further dilution ('You may experience additional dilution in the future') and a 'limited operating history' with no assurance of ever reaching profitability.
Is UPXI a buy? The one-page verdict, explained →
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $24.1M | $23.1M | $36.4M | $26.0M | $15.8M |
| Gross profit | $11.9M | $14.9M | $21.0M | $12.8M | $10.9M |
| Operating income | $1.43M | -$6.49M | -$12.3M | -$22.5M | -$12.5M |
| Net income | $2.98M | -$2.05M | -$17.5M | -$23.7M | -$13.7M |
| Diluted EPS | $0.21 | -$0.43 | -$18.94 | -$23.03 | -$1.73 |
| Net margin | 12.4% | -8.9% | -48.0% | -91.0% | -86.5% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Other-events press release, likely a Solana-treasury update; no P&L or structural change
Received Nasdaq deficiency notice—sub-$1 bid price now threatens continued listing
New financing agreement + unregistered share sale to fund SOL treasury; dilutive
Announced material deal + unregistered equity raise (Reg FD); further dilution
Reported annual-meeting voting results; routine governance, no financial impact
Released Q3 FY26 results; core sales still shrinking, operating losses continue
Q3 FY26: ongoing operating losses; Solana treasury now core balance-sheet asset
Filed proxy for annual meeting—director elections/routine votes; no financial change
Q2 FY26: continued losses; SOL treasury strategy scaling on the balance sheet
Sources: SEC EDGAR (CIK 0001775194, latest 10-Q filed 2026-05-12) · EODHD · Proprietary analysis · as of 7/3/2026, 4:42:24 PM.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 3, 2026, 12:42 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
| 2025-12-23-05:00 | MARSHALL ALLAN Chief Executive Officer | Buy | 50.0K @ $1.80 | $90.0K |
| 2025-12-16-05:00 | MARSHALL ALLAN Chief Executive Officer | Buy | 50.0K @ $2.07 | $103K |
| 2025-12-15-05:00 | MARSHALL ALLAN Chief Executive Officer | Buy | 100K @ $2.07 | $207K |
| 2025-11-20-05:00 | Salkind Gene Director | Buy | 50.0K @ $2.55 | $127K |
| 2025-11-17-05:00 | Salkind Gene Director | Buy | 100K @ $2.65 | $265K |
| 2025-11-17-05:00 | Salkind Gene Director | Buy | 100K @ $2.81 | $281K |
| 2025-10-01-05:00 | MARSHALL ALLAN Chief Executive Officer | Award | 1.60M | |
| 2025-10-01-05:00 | Norstrud Andrew James Chief Financial Officer | Award | 240K | |
| 2025-07-22-05:00 | Dugan Lawrence Director | Buy | 4.00K @ $7.50 | $30.0K |
| 2025-07-16-05:00 | Salkind Gene Director | Award | 50.0K | |
| 2025-07-16-05:00 | Salkind Gene Director | Award | 150K | |
| 2025-07-16-05:00 | Rudick Brian Benjamin CSO | Award | 400K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1195 tracked peers · median